open access

Vol 49, No 1 (2011)
Original paper
Published online: 2011-04-19
Submitted: 2011-12-19
Get Citation

CD3+/CD16+CD56+ cell numbers in peripheral blood are correlated with higher tumor burden in patients with diffuse large B-cell lymphoma

Iwona Hus, Elżbieta Starosławska, Agnieszka Bojarska-Junak, Aneta Dobrzyńska-Rutkowska, Agata Surdacka, Paulina Wdowiak, Magdalena Wasiak, Maria Kusz, Anna Twardosz, Anna Dmoszyńska, Jacek Roliński
DOI: 10.5603/FHC.2011.0025
·
Folia Histochem Cytobiol 2011;49(1):183-187.

open access

Vol 49, No 1 (2011)
ORIGINAL PAPERS
Published online: 2011-04-19
Submitted: 2011-12-19

Abstract

Diffuse large B-cell lymphoma is the commonest histological type of malignant lymphoma, and remains incurable in many cases. Developing more efficient immunotherapy strategies will require better understanding of the disorders of immune responses in cancer patients. NKT (natural killer-like T) cells were originally described as a unique population of T cells with the co-expression of NK cell markers. Apart from their role in protecting against microbial pathogens and controlling autoimmune diseases, NKT cells have been recently revealed as one of the key players in the immune responses against tumors. The objective of this study was to evaluate the frequency of CD3+/CD16+CD56+ cells in the peripheral blood of 28 diffuse large B-cell lymphoma (DLBCL) patients in correlation with clinical and laboratory parameters. Median percentages of CD3+/CD16+CD56+ were significantly lower in patients with DLBCL compared to healthy donors (7.37% vs. 9.01%, p = 0.01; 4.60% vs. 5.81%, p = 0.03), although there were no differences in absolute counts. The frequency and the absolute numbers of CD3+/CD16+CD56+ cells were lower in advanced clinical stages than in earlier ones. The median percentage of CD3+/CD16+CD56+ cells in patients in Ann Arbor stages 1–2 was 5.55% vs. 3.15% in stages 3–4 (p = 0.02), with median absolute counts respectively 0.26 G/L vs. 0.41 G/L (p = = 0.02). The percentage and absolute numbers of CD3+/CD16+CD56+ cells were significantly higher in DL -BCL patients without B-symptoms compared to the patients with B-symptoms, (5.51% vs. 2.46%, p = 0.04; 0.21 G/L vs. 0.44 G/L, p = 0.04). The percentage of CD3+/CD16+CD56+ cells correlated adversely with serum lactate dehydrogenase (R= –445; p < 0.05) which might influence NKT count. These figures suggest a relationship between higher tumor burden and more aggressive disease and decreased NKT numbers. But it remains to be explained whether low NKT cell counts in the peripheral blood of patients with DLBCL are the result of their suppression by the tumor cells, or their migration to affected lymph nodes or organs. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 1, pp. 183–187)

Abstract

Diffuse large B-cell lymphoma is the commonest histological type of malignant lymphoma, and remains incurable in many cases. Developing more efficient immunotherapy strategies will require better understanding of the disorders of immune responses in cancer patients. NKT (natural killer-like T) cells were originally described as a unique population of T cells with the co-expression of NK cell markers. Apart from their role in protecting against microbial pathogens and controlling autoimmune diseases, NKT cells have been recently revealed as one of the key players in the immune responses against tumors. The objective of this study was to evaluate the frequency of CD3+/CD16+CD56+ cells in the peripheral blood of 28 diffuse large B-cell lymphoma (DLBCL) patients in correlation with clinical and laboratory parameters. Median percentages of CD3+/CD16+CD56+ were significantly lower in patients with DLBCL compared to healthy donors (7.37% vs. 9.01%, p = 0.01; 4.60% vs. 5.81%, p = 0.03), although there were no differences in absolute counts. The frequency and the absolute numbers of CD3+/CD16+CD56+ cells were lower in advanced clinical stages than in earlier ones. The median percentage of CD3+/CD16+CD56+ cells in patients in Ann Arbor stages 1–2 was 5.55% vs. 3.15% in stages 3–4 (p = 0.02), with median absolute counts respectively 0.26 G/L vs. 0.41 G/L (p = = 0.02). The percentage and absolute numbers of CD3+/CD16+CD56+ cells were significantly higher in DL -BCL patients without B-symptoms compared to the patients with B-symptoms, (5.51% vs. 2.46%, p = 0.04; 0.21 G/L vs. 0.44 G/L, p = 0.04). The percentage of CD3+/CD16+CD56+ cells correlated adversely with serum lactate dehydrogenase (R= –445; p < 0.05) which might influence NKT count. These figures suggest a relationship between higher tumor burden and more aggressive disease and decreased NKT numbers. But it remains to be explained whether low NKT cell counts in the peripheral blood of patients with DLBCL are the result of their suppression by the tumor cells, or their migration to affected lymph nodes or organs. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 1, pp. 183–187)
Get Citation

Keywords

diffuse large B-cell lymphoma; anti-tumor immunity; CD3+/CD16+CD56+ cells

About this article
Title

CD3+/CD16+CD56+ cell numbers in peripheral blood are correlated with higher tumor burden in patients with diffuse large B-cell lymphoma

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 49, No 1 (2011)

Article type

Original paper

Pages

183-187

Published online

2011-04-19

DOI

10.5603/FHC.2011.0025

Bibliographic record

Folia Histochem Cytobiol 2011;49(1):183-187.

Keywords

diffuse large B-cell lymphoma
anti-tumor immunity
CD3+/CD16+CD56+ cells

Authors

Iwona Hus
Elżbieta Starosławska
Agnieszka Bojarska-Junak
Aneta Dobrzyńska-Rutkowska
Agata Surdacka
Paulina Wdowiak
Magdalena Wasiak
Maria Kusz
Anna Twardosz
Anna Dmoszyńska
Jacek Roliński

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl